CDK4 EXPRESSION

CI-VAR-00000891Explore in graph →CIViC 25

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Sarcoma1
CDK4 EXPRESSION	Palbociclib	Predictive	D	Supports Sensitivity Response	4	accepted	EID4872 A preclinical study to explore the efficacy of CDK4/6 inhibition with palbociclib, in a panel of sarcoma cell lines and sarcoma tumor xenografts (PDXs). The responsiveness of these cell lines correlat… (full text at CIViC) PMID 26528855 · Perez et al., 2015 · Open in CIViC	civic
Childhood B-cell Acute Lymphoblastic Leukemia1unmapped disease
CDK4 EXPRESSION	Dexamethasone + RibociclibCombination	Predictive	D	Supports Sensitivity Response	2	accepted	EID7798 CDK4 was found to be significantly overexpressed in the bone marrow of MLL-rearranged B-ALL patients (n=70) compared to normal bone marrow (n=74, p<.001). Combination treatment with dexamethasone (glu…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Estrogen Receptor-positive Breast Cancer2unmapped disease
CDK4 EXPRESSION	Alpelisib	Predictive	D	Supports Sensitivity Response	4	accepted	EID264 In mouse xenograft studies of PIK3CA mutant breast cancers, the combination of PI3K and CDK4/6 inhibitors overcomes intrinsic and adaptive resistance leading to tumor regressions. PMID 25002028 · Vora et al., 2014 · Open in CIViC	civic
CDK4 EXPRESSION	Palbociclib	Predictive	B	Supports Sensitivity Response	3	rejected	EID345 Palbociclib has been shown to dramatically improve progression-free survival by over 18 months in patients with ER+ Breast Cancer. PMID 23898052 · Logan et al., 2013 · Open in CIViC	civic